December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Ocular Pulse Amplitude in Primary Open Angle Glaucoma Patients on Brimonidine
Author Affiliations & Notes
  • DC Kazakos
    Nuffield Laboratory of Ophthalmology University of Oxford Oxford United Kingdom
  • KG Schmidt
    Oxford United Kingdom
  • AS Bernd
    Dresden Germany
  • AG Böhm
    Dresden Germany
  • LE Pillunat
    Dresden Germany
  • Footnotes
    Commercial Relationships   D.C. Kazakos, None; K.G. Schmidt, None; A.S. Bernd, None; A.G. Böhm, None; L.E. Pillunat, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 845. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      DC Kazakos, KG Schmidt, AS Bernd, AG Böhm, LE Pillunat; Ocular Pulse Amplitude in Primary Open Angle Glaucoma Patients on Brimonidine . Invest. Ophthalmol. Vis. Sci. 2002;43(13):845.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Evidence has progressively accumulated over the years to suggest that vascular insufficiency plays an important part in the pathogenesis of glaucomatous optic neuropathy. Thus antiglaucomatous drugs - in addition to reducing intraocular pressure - should not impair perfusion to the optic nerve head, the area of primary damage in this group of multifaceted diseases. This study was designed to evaluate the influence of brimonidine, a potentially vasoconstrictive alpha-2-adrenoceptor agonist, on the ocular pulse amplitude (OPA) in primary open angle glaucoma (POAG) patients. Methods: The influence of standard dosage brimonidine (0.2%, BID, one eye) on OPA (OBF-System, OBF Labs, U.K.), and systemic perfusion parameters was determined in 17 POAG patients. Measurements were taken before and after four weeks of brimonidine therapy. Results: Values represent mean SD. When compared to pretreatment values OPA (2.1 0.1/2.1 0.1 mmHg) and systemic perfusion parameters (RR syst. 142.5 10.2/137.9 9.4 mmHg, RR diast. 87.0 6.0/85.7 6.6 mmHg, heart rate 62.7 6.1/59.3 6.5 min-1) were not significantly (p≷ 0.05) altered following application of brimonidine. Conclusion: A negative effect of brimonidine on OPA in POAG patients was excluded by this study.

Keywords: 444 intraocular pressure • 499 optic flow 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.